The effect of a low FODMAP diet on luminal microbiota, fermentation and symptoms

Submission date	Recruitment status No longer recruiting	Prospectively registered		
22/01/2010		[] Protocol		
Registration date	Overall study status	[_] Statistical analysis plan		
08/03/2010	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
14/11/2013	Digestive System			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr Kevin Whelan

Contact details

4.06 Franklin Wilkins Building King's College London 150 Stamford St London United Kingdom SE1 9NH

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

The effect of a low FODMAP diet on luminal microbiota, fermentation and symptoms: A randomised controlled trial

Study objectives

H0: there will be no significant difference in the concentration of faecal bifidobacteria in patients with Irritable Bowel Syndrome (IBS) following a low FODMAP diet (intervention) compared with those following a normal diet (control) for four weeks.

H1: there will be a significant difference in the concentration of faecal bifidobacteria in patients with IBS following a low Fermentable Oligo-, Di-, and Monosaccharides and Polyol (FODMAP) diet (intervention) compared with those following a normal diet (control) for four weeks.

Ethics approval required

Old ethics approval format

Ethics approval(s) Guy's Research Ethics Committee, 11/11/2009, ref: 09/H0804/89

Study design Randomised controlled parallel group trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Other

Study type(s)

Treatment

Participant information sheet Not available in web format, please use contact details below to request a patient information sheet.

Health condition(s) or problem(s) studied

Irritable bowel syndrome

Interventions

4-week low FODMAP diet compared to usual diet. Patients in the intervention group will receive individualised dietary advice. A low FODMAP diet is a diet low in poorly absorbed fermentable carbohydrates. Patients will follow the diet for 4 weeks. The total duration of the study will be 5 weeks.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

To assess the effect of a low FODMAP diet on faecal microbiota in patients with IBS. Faecal samples will be collected at baseline and at 4 weeks.

Secondary outcome measures

1. To assess the effect of a low FODMAP diet on faecal Short Chain Fatty Acid (SCFA), pH and faecal water in patients with IBS.

2. To assess the effect of a low FODMAP diet on symptoms in patients with IBS.

3. To assess the effect of a low FODMAP diet on stool consistency and frequency in patients with IBS.

4. To assess the nutritional adequacy of a low FODMAP diet in patients with IBS.

- 5. To assess the acceptability of a low FODMAP diet in IBS patients.
- 6. Weight and height.

Outcomes will be assessed at baseline and at 4 weeks. Patients will keep a symptom diary and diet diary, and 2 questionnaires will be used to assess nutritional adequacy, FODMAP intake and diet acceptability.

Overall study start date

01/02/2010

Completion date

31/12/2010

Eligibility

Key inclusion criteria

Patients will be recruited from Gastrointestinal and Dietetic Outpatient clinics at Guys and St Thomas NHS Foundation Trust, London, UK.

1. Adult patients aged 18-65 years

- 2. Identified as having IBS based on Rome III criteria
- 3. Symptoms including bloating and/or diarrhoea

Participant type(s) Patient

Age group Adult

Lower age limit 18 Years

Upper age limit 65 Years

Sex

Both

Target number of participants

Key exclusion criteria

1. Patients with any other gastrointestinal disease or gastrointestinal surgery

2. Patients whose major IBS symptom is constipation

3. Patients receiving lactulose or any other probiotic or prebiotic substances in the four weeks prior to the study

4. Patients who have taken antibiotics in the 4 weeks prior to the study

5. Patients who have received bowel preparation for investigative procedures in the 4 weeks prior to the study

6. Patients with any other significant major organ disorders, including diabetes, psychiatric and current eating disorders

7. Patients who report to be pregnant or lactating

8. Patients who have had changes to IBS medications or dose in the 4 weeks prior to the study

Date of first enrolment 01/02/2010

Date of final enrolment 31/12/2010

Locations

Countries of recruitment England

United Kingdom

Study participating centre 4.06 Franklin Wilkins Building London United Kingdom SE1 9NH

Sponsor information

Organisation King's College London (UK)

Sponsor details

Hodgkin Building Guy's Campus Kings College London LondonSE1 1UL UNITED KINGDOM London England United Kingdom SE1 1UL

Sponsor type University/education

ROR https://ror.org/0220mzb33

Funder(s)

Funder type University/education

Funder Name King's College London (UK)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs					
Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2012		Yes	No